Archer Investment Corp Acquires 325 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

Archer Investment Corp increased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 41.1% during the 1st quarter, HoldingsChannel reports. The firm owned 1,115 shares of the biotechnology company’s stock after purchasing an additional 325 shares during the period. Archer Investment Corp’s holdings in United Therapeutics were worth $344,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of UTHR. Dunhill Financial LLC lifted its stake in United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 50 shares in the last quarter. Sound Income Strategies LLC bought a new stake in United Therapeutics in the 1st quarter valued at approximately $49,000. State of Wyoming bought a new stake in United Therapeutics in the 4th quarter valued at approximately $62,000. Curat Global LLC bought a new stake in United Therapeutics in the 1st quarter valued at approximately $63,000. Finally, Millstone Evans Group LLC bought a new stake in United Therapeutics in the 4th quarter valued at approximately $67,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Down 0.6%

Shares of UTHR stock traded down $1.86 during trading on Friday, reaching $295.47. 17,255 shares of the company’s stock were exchanged, compared to its average volume of 441,239. The stock has a market capitalization of $13.33 billion, a PE ratio of 11.79, a PEG ratio of 6.52 and a beta of 0.53. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $417.82. The firm’s fifty day moving average price is $300.61 and its 200-day moving average price is $318.55.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping analysts’ consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The firm’s revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $6.17 EPS. As a group, analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of the business’s stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the transaction, the executive vice president directly owned 36,781 shares of the company’s stock, valued at approximately $10,297,208.76. The trade was a 23.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Raymond Dwek sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $285.57, for a total value of $856,710.00. Following the transaction, the director directly owned 1,750 shares in the company, valued at $499,747.50. The trade was a 63.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 73,681 shares of company stock worth $22,140,089 in the last three months. 10.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Cantor Fitzgerald assumed coverage on United Therapeutics in a research note on Monday, June 2nd. They issued an “overweight” rating and a $405.00 target price on the stock. Wall Street Zen cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 2nd. UBS Group cut their target price on United Therapeutics from $410.00 to $385.00 and set a “buy” rating on the stock in a research note on Monday, June 30th. Morgan Stanley cut their target price on United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a research report on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $383.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.